Capricor Therapeutics Inc Stock Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Sales 2024 * | 21.4M 29.26M | Sales 2025 * | 89.52M 122M | Capitalization | 169M 231M |
---|---|---|---|---|---|
Net income 2024 * | -33M -45.12M | Net income 2025 * | 8M 10.94M | EV / Sales 2024 * | 7.91 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-5.56
x | P/E ratio 2025 * |
55.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.66% |
Latest transcript on Capricor Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
1st Jan change | Capi. | |
---|---|---|
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |